AIDS/LifeCycle benefits, and is jointly produced by, San Francisco AIDS Foundation (Tax ID # 94-2927405) and Los Angeles LGBT Center (Tax ID # 95-3567895), each of which is a nonprofit, public benefit corporation recognized as tax exempt under IRS Code Section 501(c)(3). Donations to AIDS/LifeCycle are deductible for income tax purposes, to the extent permitted by law.
National and Global Efforts
HOW YOUR GIFT CAN MAKE A DIFFERENCE
When you support AIDS/LifeCycle, you support the many national and global efforts of San Francisco AIDS Foundation, and the Los Angeles LGBT Center to improve health and well-being of people who are living with or at risk of HIV/AIDS and to prevent new HIV infections.
Information & Resources:
Annually, more than one million people from across the country and around the world visit San Francisco AIDS Foundation’s online resources for HIV and health education, information, and tools.
- BETA Blog - One of the only online resources of its kind, BETABlog.org reports on the latest developments in HIV prevention, treatment, and care, as well as gay men’s health and wellness.
- PrEPfacts.org - The Foundation also produces PrEPfacts.org, one of the nation’s first and most well-respected online resources for information about pre-exposure prophylaxis (PrEP) (a treatment in which HIV-negative people take antiretroviral medication daily to reduce their chances of becoming infected with HIV).
Treatment and Care
Since the earliest days of the epidemic, the Los Angeles LGBT Center — the world’s largest provider of programs and services for LGBT people – has been providing leading-edge and affordable HIV/AIDS medical care. People travel to the Center from throughout California and four neighboring states for treatment, and medical providers from other countries travel there for training and advice on how best to care for people living with HIV.
The dedicated policy staff of the Foundation and the Center extends the impact of donations to AIDS/LifeCycle far beyond San Francisco and Los Angeles by working at all levels of government to ensure that federal programs and funding levels sufficiently address the needs of those living with HIV, and that HIV/AIDS issues remain a top priority for lawmakers.
- National HIV/AIDS Strategy - The Foundation and the Center played key roles in developing the first blueprint to end the epidemic in the U.S.
- Ryan White and ADAP - Working closely with a range of national HIV/AIDS organizations, the Center and Foundation were architects of the original Ryan White HIV/AIDS Care Act, and have been key players in its subsequent four reauthorizations. Through Ryan White and the AIDS Drug Assistance Program (ADAP), they have increased federal funding for universal access to life-saving clinical care and medications, benefiting people throughout the country.
- Housing - In partnership with community and national organizations, the Foundation and the Center, were instrumental in helping expand housing opportunities for all people living with HIV/AIDS, including federal legislation in 2014 that ensured an additional $3 million to help people living with HIV/AIDS get affordable housing.
- Statewide Partnerships - The Center and Foundation provide statewide leadership, in coalition with other HIV/AIDS organizations, to develop legislation like the bill introduced in 2014 to smooth the transition for those whose care is now funded by the Affordable Care Act (ACA) rather than Ryan White. Locally, they conduct community outreach to help people learn about and enroll in the ACA.
The Foundation works closely with the U.S. Centers for Disease Control and Prevention to establish guidance on how to administer pre-exposure prophylaxis (PrEP) and to develop the first national HIV Prevention media campaign targeted to young Black gay men, "Testing Makes Us Stronger".
On the education front, the Foundation partners with the HIV Vaccine Trials Network and HIV Prevention Trials Network to help build a supportive environment for HIV prevention research including the creation of educational outreach materials providing accurate information about HIV research nationwide.
The Center’s renowned Clinical Research Program conducts research studies and clinical trials that contribute to scientific knowledge regarding the prevention, intervention, and treatment of HIV and other sexually transmitted infections. The research staff are vital community partners with the U.S. Centers for Disease Control, National Institutes of Health, UCLA, USC, UCSF and other institutions.
Aligned with the National HIV/AIDS Strategy, the Center’s research focuses on intervening at every stage of HIV infection. Current projects include:
- New Drug Research – For 17 years, the Center has been investigating the safety and effectiveness of new medicine to address drug resistance, reduce side effects, and simplify drug regimens. The Center’s research has contributed to the FDA approval of two new multi-class, once-a-day anti-retroviral medications.
- Biomedical Device Studies – The Center recently completed a trial of a rapid HIV test – a cost-effective, easily administered finger-stick test that can help identify ‘acute’ HIV infections (early infections that have a higher chance of transmission). This test is now used widely in sub-Saharan Africa and other underdeveloped areas of the world.
- Behavioral Research – The Center is part of a large-scale study of how Pre-Exposure Prophylaxis (PrEP) could reduce HIV transmission to a level where AIDS is no longer considered an epidemic. It is also studying how substance abuse contributes to HIV infection among gay/bi African American and Latino men, who have the highest rates of HIV infection in the U.S.
- Multi-site AIDS Cohort Study (MACS) - First funded by the National Institute for Allergy and Infectious Disease in 1983, MACS is the largest and longest-running study of the natural history of HIV/AIDS. The MACS has accumulated vast amounts of crucial data that have contributed immeasurably to the study and understanding of the virus, its treatment, and prevention.
- Academic - The Center is a vital community partner for academic, research-intensive institutions such as UCLA, USC, and RAND. Recent collaborations have focused on substance use in minority MSM communities, and innovative use of technology, such as retention and adherence to HIV/AIDS treatment through the use of mobile devices.